Gilead's Kite doubles down on Arcellx's blood cancer cell therapies with $285M
Gilead’s cell therapy unit Kite wants more of what it initially got from Arcellx last December, buying $200 million worth of equity in Arcellx and …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
